Verquvo(vericiguat)
Verquvo (vericiguat) is a small molecule pharmaceutical. Vericiguat was first approved as Verquvo on 2021-01-19. It has been approved in Europe to treat heart failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Verquvo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vericiguat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VERQUVO | Merck & Co | N-214377 RX | 2021-01-19 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| verquvo | New Drug Application | 2023-10-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VERICIGUAT, VERQUVO, MERCK SHARP DOHME | |||
| 2026-01-19 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 4 | 6 | 4 | 5 | 9 | 27 |
| Syndrome | D013577 | — | — | — | 2 | — | 1 | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 2 | — | 2 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | 1 | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 1 | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | — | — | 1 | — | 1 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Left ventricular dysfunction | D018487 | — | — | — | 1 | 2 | — | — | 2 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 2 | — | — | — | 2 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | — | — | 1 |
| Metabolism | D008660 | GO_0008152 | — | — | 1 | — | — | — | 1 |
| Energy metabolism | D004734 | — | — | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | 3 | — | — | — | — | 3 |
| Coronary artery disease | D003324 | — | I25.1 | 3 | — | — | — | — | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vericiguat |
| INN | vericiguat |
| Description | Vericiguat is a pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. It has a role as a soluble guanylate cyclase activator, a vasodilator agent and an antihypertensive agent. It is an aminopyrimidine, a pyrazolopyridine, a carbamate ester and an organofluorine compound. |
| Classification | Small molecule |
| Drug class | guanaline cyclase activators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N |
Identifiers
| PDB | — |
| CAS-ID | 1350653-20-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4066936 |
| ChEBI ID | — |
| PubChem CID | 54674461 |
| DrugBank | DB15456 |
| UNII ID | LV66ADM269 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Verquvo – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 871 documents
View more details
Safety
Black-box Warning
Black-box warning for: Verquvo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
726 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use